Hananja

Welcome to Hananja

Emerging data presented by USL in San Diego Epilepsy and Neurology meetings 2012 & 2013

Upsher-Smith Laboratories released a press release on November 26th, 2012 on their committed to the development of new treatments for e.g. epilepsy. They are proud to sponsor emerging data on USL261, its novel formulation of intranasal midazolam, at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, CA, November 30 – December 4, 2012.

Read more...
 

PREECLAMPSIA: A NEW TREATMENT USING ECLAMPSIN.

Hananja plc has discovered the effect of eclampsin (placental protein 13) on uterine arteries
together with its collaborators in Dr. Hamutal Meiri (Israel) and Dr. Berthold Huppertz
(Austria). The first data have been accepted for publication in Fetal Diagnosis and Therapy
under the title:

Read more...

   

EPILEPTIC SEIZURES: NEW EFFECTIVE TREATMENT IN SIGHT

Intranasal delivery
Epilepsy is caused by disturbed electrical activity in the brain and has been recognized for at
least 2400 years. It is expressed as a collection of many different types of seizures that vary
widely in severity, appearance, cause, consequence and management. Its most severe form,
status epilepticus, is a neurological emergency that may result in brain damage or death.
Seizures should be treated as soon as possible. From onset of seizures and until the initiation
of the treatment should be as short as possible, to reduce the damage seizures can cause as
well as the risk of morbidity and mortality.

 

 

Read more...
   

Page 2 of 3

Þú ert hér: Home

Support center

Hananja plc

  • Address: Aflagrandi 7
  • City: 107 Reykjavík, Iceland
  • Tel: (+354) 898-0318
  • Email: sg@hananja.com